• Earlier this month, Krystal Biotech reported a positive interim update from the highest-dose cohort of its Phase 1 CORAL-1 study, showing successful lung delivery and expression of wild-type CFTR protein with inhaled gene therapy candidate KB407 in cystic fibrosis patients.
• This progress in validating in-lung gene delivery with KB407 adds a new potential pillar to Krystal’s HSV-1-based platform beyond its existing dermatology franchise.
• We’ll now examine how KB407’s early success in achieving lung CFTR expression may influence Krystal Biotech’s investment narrative and risk profile.

Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.

Krystal Biotech Investment Narrative Recap

To own Krystal Biotech, you need to believe its HSV 1 gene delivery platform can support multiple commercial rare disease products, reducing dependence on VYJUVEK over time. The positive KB407 CORAL 1 update strengthens the lung franchise story but does not immediately change the near term focus on VYJUVEK execution and international reimbursement risk, which still looks like the key swing factor for the business.

Among recent announcements, Krystal’s preliminary 2025 VYJUVEK revenue of about US$388 million to US$389 million and its goal of at least four marketed rare disease medicines by 2030 are most relevant. They show how KB407 fits into a broader effort to diversify beyond a single product while continued global rollout, especially in Europe and Japan, remains a central catalyst that investors are watching closely.

However, while KB407 broadens the story, investors should also be aware of the risk that high and rising SG&A and R&D spend could...

Krystal Biotech's narrative projects $849.4 million revenue and $485.8 million earnings by 2028. This requires 33.2% yearly revenue growth and about a $339 million earnings increase from $146.7 million today.

Uncover how Krystal Biotech's forecasts yield a $223.00 fair value, a 22% downside to its current price.

Exploring Other Perspectives

Three fair value estimates from the Simply Wall St Community span roughly US$202 to US$556 per share, showing very different expectations. You can weigh these views against Krystal’s growing reliance on new pipeline catalysts like KB407 to reduce concentration in VYJUVEK and consider how that balance might influence the company’s long term performance.

Explore 3 other fair value estimates on Krystal Biotech - why the stock might be worth 29% less than the current price!

Build Your Own Krystal Biotech Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Krystal Biotech research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Krystal Biotech research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Krystal Biotech's overall financial health at a glance.

Looking For Alternative Opportunities?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Outshine the giants: these 24 early-stage AI stocks could fund your retirement.
• We've found 12 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• Explore 23 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.